Mortality after high-risk myocardial infarction over the last 20&#x2009;years: Insights from the VALIANT and PARADISE-MI trials

Heart, Artery and Coronary Diseases

Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data

Eur J Heart Fail

Amir O, Elbaz-Greener G, Carasso S, Claggett B, Barbarash O, Zaman A, Christersson C, Kiatchoosakun S, Anonuevo J, Opolski G, Vaghaiwalla MF, van der Meer P, Zhou Y, Mann DL, Kober L, Steg G, Jering K, Kulac I, De Pasquale CG, McMurray JJV, Pfeffer MA, PARADISE‐MI Investigators and Committees

doi: 10.1002/ejhf.3542

Heart, Artery and Coronary Diseases

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Am Heart J

Steg PG, Nicolas J, Baber U, Sartori S, Zhang Z, Feng Y, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Marx SO, Kornowski R, Kunadian V, Vogel B, Oliva A, Mehta SR, Moliterno D, Sardella G, Krucoff M, Shlofmitz RA, Sharma S, Pocock S, Mehran R

doi: 10.1016/j.ahj.2025.01.016

Heart, Artery and Coronary Diseases

Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial

Eur J Heart Fail

Petrie MC, Udell JA, Anker SD, Harrington J, Jones WS, Mattheus M, Gasior T, van der Meer P, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chopra VK, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Butler J

doi: 10.1002/ejhf.3548

Myocardial Infarction

10-Year Mortality After ST-Segment Elevation Myocardial Infarction Compared to the General Population

J Am Coll Cardiol

Thrane PG, Olesen KKW, Thim T, Gyldenkerne C, Hansen MK, Stødkilde-Jørgensen N, Jakobsen L, Bødtker Mortensen M, Dalby Kristensen S, Maeng M

doi: 10.1016/j.jacc.2024.04.025

Heart, Artery and Coronary DiseasesFurther Publications

Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials

JAMA Cardiol

Bhatt AS, Johansen ND, Vaduganathan M, Modin D, Pareek M, Chatur S, Claggett BL, Janstrup KH, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Dueger EL, Samson S, Loiacono MM, Harris RC, Køber L, Solomon SD, Martel CJ, Sivapalan P, Jensen JUS, Biering-Sørensen T

doi: 10.1001/jamacardio.2024.4648

Myocardial Infarction

Culprit-Only Revascularization, Single-Setting Complete Revascularization, and Staged Complete Revascularization in Acute Myocardial Infarction: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials

Circ Cardiovasc Interv

Maqsood MH, Tamis-Holland JE, Rao SV, Stone GW, Bangalore S

doi: 10.1161/CIRCINTERVENTIONS.123.013737

Myocardial InfarctionFurther Publications

Sudden cardiac death after early-onset myocardial infarction. A multicentre longitudinal cohort study with 20 years' follow-up

Eur Heart J Acute Cardiovasc Care

Bricoli S, Magnani G, Ardissino M, Maglietta G, Celli P, Ferrario M, Canosi U, Cernetti C, Negri F, Merlini PA, Tubaro M, Berzuini C, Manzalini C, Moschini L, Ponte E, Pozzi R, Buratti S, Botti A, Barocelli F, Biagi A, Bonura R, Bearzot L, Moccetti T, Crocamo A, Notarangelo MF, Moscarella E, Calabrò P, Niccoli G, Ardissino D

doi: 10.1093/ehjacc/zuae089

Myocardial Infarction

Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction

Am Heart J

d'Entremont MA, Lee SF, Mian R, Kedev S, Montalescot G, Cornel JH, Stankovic G, Moreno R, Storey RF, Henry TD, Skuriat E, Tyrwhitt J, Mehta SR, Devereaux PJ, Eikelboom J, Cairns JA, Pitt B, Jolly SS

doi: 10.1016/j.ahj.2024.06.007

Myocardial Infarction

Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial

JAMA Intern Med

Ujueta F, Lamas GA, Anstrom KJ, Navas-Acien A, Boineau R, Rosenberg Y, Stylianou M, Jones TLZ, Joubert BR, Yu Q, Wen J, Nemeth H, Huang Z, Fonseca V, Nathan DM, Uwaifo G, Arenas IA, Luo L, Baker J, Visentin D, Paixao A, Schmedtje JF Jr, Mark DB, TACT2 Investigators

doi: 10.1001/jamainternmed.2024.8408

Cardiovascular

Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trials

Related content

Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial

10-Year Mortality After ST-Segment Elevation Myocardial Infarction Compared to the General Population

Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials

Culprit-Only Revascularization, Single-Setting Complete Revascularization, and Staged Complete Revascularization in Acute Myocardial Infarction: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials

Sudden cardiac death after early-onset myocardial infarction. A multicentre longitudinal cohort study with 20 years' follow-up

Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction

Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial